Last edition
News about "atopic dermatitis "
ImageneBio Raises USD 30 Million in Private Placement
ImageneBio has raised USD 30 million in private placement led by Coastlands Capital to advance IMG-007 development in alopecia areata and atopic dermatitis.
Atopic Dermatitis | 14/04/2026 | By News Bureau
Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study
Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.
Atopic Dermatitis | 30/03/2026 | By News Bureau
EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis
In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.
Atopic Dermatitis | 17/03/2026 | By Akanki
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
Atopic Dermatitis | 10/03/2026 | By News Bureau | 113
Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Atopic Dermatitis | 16/12/2025 | By News Bureau | 283
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
Atopic Dermatitis | 14/10/2025 | By Dineshwori | 528
Amgen and Kyowa Kirin Report Phase-III Results for Rocatinlimab in Atopic Dermatitis
Amgen and Kyowa Kirin report top-line results from ongoing ASCEND study evaluating Rocatinlimab’s long-term safety and efficacy in adults with moderate to severe Atopic Dermatitis following prior ROCKET trials.
Atopic Dermatitis | 09/09/2025 | By Dineshwori | 237
Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis
Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.
Atopic Dermatitis | 04/09/2025 | By Dineshwori | 354
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Atopic Dermatitis | 17/09/2024 | By Aishwarya | 749
Johnson & Johnson to Acquire Proteologix to Expand its Portfolio
Johnson & Johnson has signed a definitive agreement to acquire Proteologix, Inc. for USD 850 million in cash, with the potential for an additional milestone payment.
Atopic Dermatitis | 17/05/2024 | By Aishwarya | 718
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy